Katsuaki Maehara ,Director of Medical Education Colleagues, shared a post on X:

“ EGFR-mutated oligo-organ metastatic NSCLC
A murticenter, randomized, controlled, Phase III
First-line EGFR-TKIs, concurrent TRT improves the PFS & OS.

Katsuaki Maehara

TKI + TRT – Higher incidence of severe TRAEs.

EGFR-mutated oligo-organ metastatic NSCLC, summarised by Katsuaki Maehara

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial

Authors: Hongfu Sun, Minghao Li, Wei Huang, Jian Zhang, Shihong Wei, Yongjing Yang, Zhongtang Wang, Shucheng Ye, Heyi Gong, Yaowen Zhang, Jie Li,Haixia Song, Lifang Wang, Xiangming Chen, Haiqun Lin, Gaofeng Ding, Hongwei Li, Anping Zheng, Xuezhen Ma, ShaoShui Chen, Liping Liu, Kaixian Zhang, Chengrui Fu,Wenzhi Liu, Jing Wang, Xiaqin Zhang, Tingting Liu, Dan Han, Qian Zhao, Peipei Wu, Qianqian Yuan,LiJun Tian, Ping Zhang, Xueqin Wu, Fei Chen, Zicheng Zhang, and Baosheng Li.

Katsuaki Maehara